Initial Experience of Platelet Glycoprotein IIb/IIIa Inhibition With Abciximab During Carotid Stenting | Zendy

Samir Kapadia | Zendy; Christopher Bajzer | Zendy; Khaled M. Ziada | Zendy; Deepak L. Bhatt | Zendy; Oussama M. Wazni | Zendy; Mitchell Silver | Zendy; Edwin G. Beven | Zendy; Kenneth Ouriel | Zendy; Jay S. Yadav | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Initial Experience of Platelet Glycoprotein IIb/IIIa Inhibition With Abciximab During Carotid Stenting

Author(s) -

Samir Kapadia,

Christopher Bajzer,

Khaled M. Ziada,

Deepak L. Bhatt,

Oussama M. Wazni,

Mitchell Silver,

Edwin G. Beven,

Kenneth Ouriel,

Jay S. Yadav

Publication year - 2001

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/hs1001.096003

Subject(s) - abciximab , medicine , carotid stenting , aspirin , stroke (engine) , anesthesia , bolus (digestion) , surgery , activated clotting time , adjunctive treatment , myocardial infarction , heparin , carotid endarterectomy , percutaneous coronary intervention , carotid arteries , mechanical engineering , engineering

Abciximab has been shown to decrease periprocedural ischemic complications after coronary intervention. However, the adjunctive use of abciximab in carotid stenting has not been adequately studied. We sought to determine the efficacy and safety of abciximab in carotid stenting.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research